期刊
ADVANCED HEALTHCARE MATERIALS
卷 8, 期 5, 页码 -出版社
WILEY
DOI: 10.1002/adhm.201800571
关键词
alginates; cancer vaccines; dendritic cells; graphene; macroporous scaffolds; slow release
资金
- Basic Science Research Program through the National Research Foundation (NRF) - Ministry of Science and ICT, Republic of Korea [2010-0027955, 2014M3A9B8023471]
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI17C0076]
Ex vivo manipulation of autologous antigen-presenting cells and their subsequent infusion back into the patient to dictate immune response is one of the promising strategies in cancer immunotherapy. Here, a 3D alginate scaffold embedded with reduced graphene oxide rGO proposed as a vaccine delivery platform for in situ long-term activation of antigen-presenting dendritic cells (DCs). High surface area and hydrophobic surface of the rGO component of the scaffold provide high loading and a very slow release of a loaded antigen, danger signal, and/or chemoattractant from the scaffold. This approach offers long-term bioavailability of the loaded cargo inside the scaffold for manipulation of recruited DCs. After mice are subcutaneously vaccinated with the macroporous alginate graphene scaffold (MACS) loaded with ovalburnin (OVA) and granulocyte-macrophage colony-stimulating factor (GM-CSF), this scaffold recruits a significantly high number of DCs, which present antigenic information via major histocompatibility complex class I for a long period. Furthermore, an MACS loaded with OVA, GM-CSF, and CpG promotes production of activated T cells and memory T cells, leading to the suppression of OVA-expressing B16 melanoma tumor growth in a prophylactic vaccination experiment. This study indicates that an MACS can be a strong candidate for long-term programming and modulating immune cells in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据